Text Size

Oxytocin, Couple Interaction and Wound Healing

This study is currently recruiting participants.
Verified October 2011 by University of Zurich
Sponsor:
Collaborator:
Swiss National Science Foundation
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT01594775
First received: May 7, 2012
Last updated: May 8, 2012
Last verified: October 2011
History of Changes
  Purpose

effects of intranasal oxytocin and couple interaction on wound healing.

  • Trial with medicinal product

Condition Intervention Phase
Healthy Volunteers
 Drug: Syntocinon (Oxytocin) nasal spray
Drug: Placebo
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Drug Reactions
Drug Information available for: Oxytocin
U.S. FDA Resources

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • wound size [ Time Frame: seven days ] [ Designated as safety issue: No ]
    wound healing process within seven days after wounding


Estimated Enrollment: 200
Study Start Date: October 2011
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: nasal spray Drug: Syntocinon (Oxytocin) nasal spray
two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
Placebo Comparator: Placebo Drug: Placebo
two-times daily self-administration of nasal spray containing placebo during five days after wounding.

  Eligibility

Ages Eligible for Study:   21 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • healthy heterosexual couples
  • in a stable relationship since > 1 year

Exclusion criteria: pregnancy

  • breast feeding
  • heavy smoking (> 5 cigarettes/d)
  • extensive skin disease
  • artificial UV irradiation during < 3 months before study inclusion
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01594775

Contacts
Contact: Beate Ditzen, PhD +41 (0)44 6357365 b.ditzen@psychologie.uzh.ch

Locations
Switzerland
University Hospital Zurich, Dept. of Dermatology Recruiting
Zurich, Switzerland, 8091
Contact: Beate Ditzen, Ph.D.     +41 44 6357365     b.ditzen@psychologie.uzh.ch    
Contact: Severin Lauchli, M.D.     +41 44 255 2811     severin.laeuchli@usz.ch    
Sponsors and Collaborators
University of Zurich
Swiss National Science Foundation
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
Principal Investigator: Severin Laeuchli, MD University Hospital Zurich, Division of Dermatology
  More Information

No publications provided

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01594775     History of Changes
Other Study ID Numbers: KEK-ZH-NR: 2009-0063
Study First Received: May 7, 2012
Last Updated: May 8, 2012
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Oxytocin
Oxytocics
Reproductive Control Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013